This activity is supported by an independent education grant from GSK. This online education program has been designed solely for healthcare professionals in the USA. The information is this program is not suitable for any other country.

Join leading experts Dr. Francis Farraye, Dr. Barbara Yawn and Dr. Ruth Carrico for this accredited virtual webinar. This is a 60-minute interactive virtual roundtable designed to identify and resolve real-world breakdowns in shingles prevention for immunocompromised adults. Led by a multidisciplinary team—this hands-on, case-based workshop models shared ownership of prevention to help ambulatory care teams strengthen protection and boost series completion rates.

Participants will engage in rapid scenario analysis, structured reflections, and interactive polling across four high-friction clinical domains, including eligibility hesitation, patient hesitancy, workflow breakdowns, and second-dose drop-offs.

Session Highlights

• Overcoming Eligibility Hesitation: Clarify decision ownership and optimal vaccination timing for immunocompromised patients receiving complex therapies.
• Addressing Patient Hesitancy: Utilize practical scripts and communication strategies to resolve patient concerns regarding vaccine reactogenicity and confidence gaps.
• Eliminating Workflow Breakdowns: Bridge gaps between primary care and specialty clinics with clear documentation and recall processes.
• Maximizing Series Completion: Implement clear delegation models and follow-up protocols to prevent second-dose drop-off in ambulatory care.

Who Should Watch

This program is designed for the following HCPs:

• Family Medicine Physicians
• Internal Medicine Physicians
• Nurse Practitioners (NPs) in primary care
• Physician Assistants (PAs) in primary care

Faculty

Dr. Francis Farraye, MD, MSc, is a gastroenterologist and clinical researcher at Mayo Clinic specializing in the management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. A prolific investigator with over 450 peer-reviewed publications, his research centers on vaccination strategies for immunosuppressed patients, evaluating the effects of GLP-1 receptor agonists on IBD activity, comparative effectiveness of IBD therapies, and optimizing surgical outcomes after ileal pouch-anal anastomosis (IPAA). Dr. Farraye serves as principal investigator on numerous industry-sponsored clinical trials delivering novel investigational therapies for refractory IBD, and his leadership has been recognized with honors including the Mayo Clinic Florida Department of Medicine Researcher of the Year and the Crohn's & Colitis Foundation Lifetime Achievement Award.

Dr. Barbara Yawn, MD, MSc, MSPH, is a family medicine physician and clinical researcher with more than a decade of experience practicing in the rural primary care setting. She is also Professor of Family and Community Health at the University of Minnesota in Minneapolis, Minnesota. Dr. Yawn started her career in rural Minnesota, providing maternity and lifelong care after birth. She began conducting research while in rural practice to address the lack of research conducted within and relevant to primary care. Today, having spent more than 25 years as a clinical researcher, Dr. Yawn has contributed to over 400 publications, 3 books, and many book chapters. She has presented her findings and primary care–focused education all over the world.

Dr. Ruth Carrico, PhD, DNP, FNP-C, FAAN, is an Infection Prevention and Control Consultant, Gratis Professor at the University of Louisville School of Medicine, and Co-Founder of the Infection Prevention Institute. With over 35 years of experience in infectious diseases and vaccinology, she previously served as a full Professor in the Division of Infectious Diseases at the University of Louisville—where she directed the Vaccine and International Travel Clinic—and held leadership roles at the Norton Infectious Diseases Institute at Norton Healthcare. Dr. Carrico earned her PhD in Management and her Doctor of Nursing Practice (DNP) from Northern Kentucky University, and is board-certified in infection control (CIC) with an Advanced Leadership Certification (AL-CIP). Her expertise and research focus on vaccine delivery workflows, immunization infrastructure, international travel medicine, and public health implementation, having served on the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC) and as editor of the APIC Text of Infection Control and Epidemiology.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Francis Farraye, MD, MSc, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for Biocon, Braintree Labs, Celltrion, Cristcot, GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Lilly, Merck, Metaphore Biotechnologies, Moderna, MoonLake, and Pfizer; Consultant for Biocon, Braintree Labs, Celltrion, Cristcot, GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Lilly, Merck, Metaphore Biotechnologies, Moderna, MoonLake, and Pfizer; Speaker for Biocon, Braintree Labs, Celltrion, Cristcot, GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Lilly, Merck, Metaphore Biotechnologies, Moderna, MoonLake, and Pfizer.

Barbara Yawn, MD, MSc, MSPH, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for AstraZeneca, Boehringer Ingelheim, and GSK; Consultant for AstraZeneca, Boehringer Ingelheim, and GSK; Speaker for AstraZeneca, Boehringer Ingelheim, and GSK.

Ruth Carrico, PhD, DNP, FNP-C, FAAN, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for American Hospital Association, GSK, Kentucky Hospital Association, Pfizer, Sanofi, Valneva, and VaxCare; Consultant for American Hospital Association, GSK, Kentucky Hospital Association, Pfizer, Sanofi, Valneva, and VaxCare; Speaker for American Hospital Association, GSK, Kentucky Hospital Association, Pfizer, Sanofi, Valneva, and VaxCare.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 18, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-348-L01-P

Type of Activity: Application

Fee Information

There is no fee for this educational activity.